Cure My Disease

Don't miss your cure!

 Log in / Sign up

Artificial intelligence could help prevent transplant complications by personalizing drug dosing

NCT ID NCT07695571

Disease control Sponsor: Yasmin medhat munir Mohamed Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This study aims to develop an artificial intelligence tool that helps doctors choose the right dose of cyclosporine for patients who have received a bone marrow transplant. Cyclosporine is used to prevent graft-versus-host disease, a serious complication where donor cells attack the patient's body. The tool combines information about how the drug behaves in the body with machine learning and deep learning techniques to predict the best dose using minimal blood samples. The goal is to make dosing more personalized and practical for everyday clinical care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cyclosporine
What this could lead to
If successful, this AI tool could help doctors personalize cyclosporine doses for each patient, potentially reducing the risk of graft-versus-host disease after bone marrow transplant.
What could go wrong
This is a modeling study, not a treatment trial. The tool's predictions may not improve real-world outcomes, and its accuracy depends on the quality of the data used.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of pediatric and adult patients aged 2-65 years who underwent first allogeneic hematopoietic stem cell transplantation (HSCT) and received cyclosporine for graft-versus-host disease (GVHD) prophylaxis. Participants will be identified retrospectively from electronic medical records and therapeutic drug monitoring (TDM) databases. Eligible patients must have complete demographic, clinical, laboratory, dosing, and cyclosporine TDM data. Patients with inaccurate dose administration or blood sampling times, missing essential covariates, or insufficient pharmacokinetic or TDM data will be excluded.

Ages

2 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * • CsA therapy indicated alone or in combination for GVHD prophylaxis. * Aged 2-65 years. * Clinically stable after first HSCT. Exclusion Criteria: * • Inaccurate sampling or dose administration times. * Patients with missing key covariates. * Patients lacking sufficient pharmacokinetic or TDM data

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AML are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AML Bone marrow transplantation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.